CALCIUM-CHANNEL BLOCKERS AND MACROLIDES - LERCANIDIPINE
Because potent inhibitors of CYP3A4 have raised lercanidipine levels by 15-fold the manufacturers predict that erythromycin will raise lercanidipine levels.
Concurrent use is contraindicated. Other macrolides may also interact, although it seems unlikely that they all will, see macrolides.
Concurrent use is contraindicated. Other macrolides may also interact, although it seems unlikely that they all will, see macrolides.